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C h a p t e r  6  
PRECLINICAL DEVELOPMENT OF PY-IM POLYAMIDES  
AS THERAPEUTICS FOR MULTIPLE MYELOMA 
 
 
 
This chapter is based on a collaborative project with Patrick J. Frost (UCLA, West Los Angeles 
Veteran Affairs Hospital). The text of this chapter was taken in part from a MERIT grant 
application submitted to West Los Angeles Veteran Affairs Hospital, written by Patrick J. Frost. 
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Introduction 
 
Multiple myeloma (MM) is an incurable disease of malignant plasma cells characterized 
by high rates of relapse, resistance to drug therapies, and, despite some recent advances in 
treatments, an overall median survival of just 5-6 years (1-3). It is unclear why this disease 
is so difficult to cure, but it has been hypothesized that physiologic characteristics of the 
bone marrow (BM) microenvironment confer critical growth and survival advantages that 
protect MM (4, 5). The BM is known to be hypoxic (pO2 ~10-30mmHg) (6) compared to 
most tissues (85-150mmHg) and paradoxically, while oxygen stress can kill tumor cells 
(7), low pO2 conditions also promote MM tumor progression (8), angiogenesis (9, 10), and 
resistance to chemotherapy (11, 12). These pro-survival effects are known to be regulated 
by an adaptive cellular response mediated by several oxygen-sensitive transcription 
factors, the most important of these being the hypoxia-inducible factors (HIFs) (for review 
see (13)). HIFs are composed of a constitutively expressed β-subunit (HIF1β/ARNT) and 
inducible α-subunits (HIF1α, 2α, and 3α) whose expression is generally dependent upon 
oxygen levels and is regulated by proteosome degradation (Fig. 6.1A). While the exact 
roles that these -subunits play in regulating the hypoxic responses of MM in the BM 
microenvironment isn’t well understood, recent studies do suggest that HIF1 activity 
supports initial survival and angiogenesis, whilst HIF2 supports subsequent MM 
progression and growth (3, 14). Thus, since the BM is known to have hypoxic niches that 
support MM growth and survival, and the adaptive cellular response to hypoxia includes 
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activation of HIF, we hypothesize that targeting this HIF-mediated adaptive hypoxic 
response will sensitize or kill MM cells engrafted within the BM microenvironment. 
 
HIF activates about ~100-200 genes, typically in “categories” related to metabolism, 
angiogenesis, and apoptosis (15, 16). Because of the development of more resistant and 
malignant tumor phenotypes associated with hypoxia, there is increasing interest to 
targeting HIF-mediated gene transcription (17). Whilst targeting HIF-mediated 
transcription may be a promising strategy, there are numerous barriers to success. For 
example, many DNA targeting/binding molecules are non-specific and have significant 
“off target” effects against tumor and normal tissue (18). Echinomycin, a cyclic peptide in 
the family of quinoxaline antibiotics, can inhibit HIF/DNA binding (19), but is less 
sequence specific than HIF-PA (20). Programmable HIF inhibitors, such as siRNA or zinc-
finger peptides, are sequence specific but suffer from poor bioavailability and the need for 
specific targeting strategies (21). Hairpin polyamides have an advantage for targeting gene 
transcription; they are small synthetic molecules, are cell permeable, localize to the nuclei, 
and can recognize and bind specific regions of the minor groove of double helical DNA 
with high affinity (22). The sequence specificity is conferred by the pattern of side-by-side 
pairs of Py and Im residues: Im-Py targets a G-C base pair, Py-Im targets a C-G base pair, 
and Py-Py targets T-A or A-T base pair (Fig. 6.1B) (23). Polyamide binding results in 
allosteric changes to the DNA helix that interferes with DNA-protein interactions and 
modifies endogenous gene expression (22). Specific PA compounds have been developed 
to recognize and target the promoter regions of enhancer and transcription factor binding 
elements, including androgen receptor (AR) (24), glucocorticoid receptor (GR) (25), NF-
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B (26), and the TGF-1 promoter region (27). In xenograft studies, polyamides  
emonstrated anti-tumor efficacy related to their ability to inhibit specific gene expression, 
thereby providing a strong justification for further pre-clinical studies (28-32). Olenyuk et 
al (33) developed a PA that targets the 5’-WTWCGW-3’ (W= A or T) sequence that 
modulates a subset of hypoxia-induced genes and confirmed that HIF/DNA targeting PA 
could be specific inhibitors of HIF activity (20).  
 
This hypothesis was tested using a class of synthetically derived, sequence-specific DNA-
binding pyrrole-imidazole (Py-Im) polyamide (PA) molecules that are composed of the 
aromatic rings of N-methylpyrrole and N-methylimidazole amino acids that recognize  
 
Fig 1: (A) Cartoon of HIF regulation showing O2-dependent 
stabilization of HIF and dimerization with HIF. (B) Cartoon 
of PA used in this study (I) HIF-PA, (2) FITC-HIF-PA, (3) CO-
PA. 
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the promoter regions of enhancer and transcription factor binding elements within DNA 
sequences (Fig. 6.1B) (33). The binding of Py-Im PA compounds results in allosteric 
changes to the DNA helix that interferes with DNA-protein interactions and modifies gene 
expression (22). These compounds have multiple advantages for targeting gene 
transcription: they are cell permeable, localize to the nuclei, and recognize and bind to 
specific regions of the minor groove of double helical DNA with affinity similar to 
transcriptional factors, such as HIF (22). Previous studies show antitumor effects of Py-Im 
polyamides in xenografts (20, 26, 28, 30); however, the effects of Py-Im polyamide 
treatment on Multiple Myeloma models have not been examined.  Herein we evaluate those 
effects using a Py-Im polyamide (HIF-PA) that is capable of displacing heterodimer from 
binding to its cognate DNA sequences and inhibiting hypoxia-mediated gene transcription 
including pro-angiogenic factors (33). The choice of compound is dictated by observed 
heightened expression of angiogenic factors, such as VEGF, increased angiogenesis within 
MM tumors, and a strong correlation of these characteristics with disease development and 
progression in the BM and poor patient prognosis (34-37). Currently used VEGF-targeting 
drugs, such as bevacizumab (Avastin) inhibit angiogenesis in MM tumors; however, only 
modest and transient anti-tumor effects were observed (38), calling into question the 
overall clinical effectiveness of using a mono-therapeutic strategy targeting angiogenesis 
to treat myeloma. One explanation for the underwhelming effects of bevacizumab could 
be explained by a concomitant increase of hypoxia resulting from the inhibition of 
angiogenesis (39). In this scenario, low pO2 (a natural component of the BM niche) may 
actually support MM progression and facilitate the adaptive hypoxic response via 
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activation HIF signaling and transcription of survival factors. In fact, a growing body 
of evidence supports the idea that HIF activity confers resistance to hypoxia-mediated 
apoptosis in solid tumors (40) and chemotherapy-mediated apoptosis in MM (12, 41). 
Thus, anti-angiogenesis strategies that don’t address the HIF-mediated adaptive response 
to hypoxia may potentiate MM survival. Here, we present preliminary data demonstrating 
that synthetically derived PA compounds specifically inhibit the HIF-mediated adaptive 
hypoxic response in MM cells and overcome their resistance to hypoxia-mediated 
apoptosis. We investigated hypoxic signaling and HIF-PA response in a panel of MM cell 
lines (U266, H929, OPM-2, MM1.S, 8226) and the IL-6 dependent ANBL-6 isogenic MM 
cell line that has been transfected with mutated N-RAS or K-RAS (42). ANBL-6 is an 
interesting model because oncogenic mutations of RAS occur in 30-40% of MM patients 
and are associated with progressive disease, resistance to therapy, poor survival, and 
induction of HIF1 (43, 44), which makes them a good candidate for targeting HIF activity. 
Another cell model used are isogenic U266 cells transfected with a constitutively activated 
AKT allele (45). The 8226 cells were used to establish subcutaneous and orthotopic (bone 
marrow) xenografts and showed potential anti-tumor effects of HIF-PA-mediated. Finally, 
our preliminary experiments silencing HIF1 expression mirror our results of targeting 
HIF activity with polyamides, thereby validating our overall strategy. Our results showing 
differential expression and regulation of HIF-subunits to low pO2 highlights the 
importance of understanding the role that these transcriptional factors play in mediating 
the hypoxic response of MM engrafted in the BM.  
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Fig 2. (A) Hypoxia-mediated apoptosis in MM cells cultured 
under normoxia (22%) or hypoxia (0.1%) for 72hr.  Brackets 
indicate significance (p<0.05). OPM2 and MDA-MB-231 cells 
were cultured at 0.1% O2 for 48hr.  Mean  Std dev of 4 
independent experiments. (B) Immunoblots of HIF1 and 2 
expression and translocation under normoxia or hypoxia for 24 
hrs.  C=cytoplasm fraction, N=nuclear fraction.  (C) CoCl2 
induction of HIF1 in OPM2. Lysates were collected at indicated 
times. (D) Immunoblots of hypoxia-mediated induction of 
HIF1 and 2 in MM cells. (E) Immunoblots showing effect of 
24 hr hypoxia on anti- and pro-apoptotic factors in 8226 and 
OPM2 cells. N=normoxia (22%), H=hypoxia (0.1%). 
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Results 
 
Regulation of hypoxic gene expression in polyamides 
MM cell lines have been reported to be resistant to hypoxia (3), but variations in the pO2 
levels studied, use of hypoxia mimicking agents (i.e., CoCl2) and variation in cell lines has 
introduced discrepancies between studies. To establish our own baseline model, we used a 
hypoxia chamber to test the sensitivity of MM cell lines cultured under standard 
“normoxic” conditions (i.e., ~22% O2, 5% CO2) or “hypoxic” conditions (from 2% down 
to 0.1% O2). The O2 levels (2-0.1%) we report here are similar to the actual pO2 levels 
observed in mouse BM; Spencer et al (6) measured pO2 in mouse bone marrow to be <32 
mmHg, but in some BM niches it could be as low as 9.9 mmHg, or about 1% O2 (range of 
2-0.6%) in the extravascular spaces. We found that pO2 levels >1% were only modestly 
cytotoxic to MM cells, even when cultured up to 72 hrs (data not shown). At low oxygen 
conditions (e.g., 0.5-0.1% O2), we observed a statistically significant (T-test, p<0.05) 
increase in hypoxia-mediated apoptosis (Fig. 6.2A) with 8226 and U266 cells being the 
most resistant (an increase of ~15-20% apoptosis), whilst H929 and MM1.S were 
intermediately sensitive (~25% apoptosis). In contrast, OPM2 was the most sensitive 
(>50% apoptosis compared) and this affect occurred by 48 hr. As a positive control for 
hypoxia-mediated apoptosis, we used the breast cancer cell line, MDA-MB-231, which is 
known to be sensitive to low pO2 (46).  The hypoxia-resistant 8226 cells constitutively 
expressed HIF1, but this was strongly upregulated by hypoxia (0.1%, 24 hrs) (Fig. 6.2B 
left panel). HIF1 was not observed in the hypoxia-sensitive OPM2 under normoxic 
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baseline conditions, but was induced by low pO2 (Fig. 6.2B, right panel). Interestingly, 
HIF2 expression was independent of O2 levels in both cell lines. This is interesting 
because both  
 
Fig. 6.3. (A) 8226 cells transfected with mock (None), HIF1 siRNA 
(HIF) or scrambled siRNA (SC) and HIF1 and HIF2 measured by 
WB. (B). HRE-LUC reporter activity in 8226 cells transfected with 
HIF siRNA or SC siRNA as described above. Values are means std 
of 3 independent experiments. NS=non significant (p>0.05), 
*=p<0.05. Hypoxic conditions were set at 0.1% for 24hrs. (C) HRE-
LUC activity in 8226 cells under normoxic or hypoxic conditions and 
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treated with PA as indicated above. (D) HIF-PA-mediated inhibition 
of VEGF mRNA by RT-PCR (*=p<0.05). (E) HIF-PA-mediated 
inhibition of VEGF in supernatants by ELISA (*=p<0.05). 
 
-subunits are controlled via the PHD/VHL ubiquination pathway, yet it isn’t clear why 
HIF2, but not HIF1, is constitutively expressed in these cells, and may lend credence to 
our hypothesis that the -subunits have differential roles in MM. The rapid upregulation 
of HIF1 in OPM2 was confirmed using the hypoxia mimic, CoCl2, which induced HIF1 
by 1hr and reached a maximum by 18hrs (Fig. 6.2C). HIF1 expression was also induced 
by low pO2 in MM1S, H929, Mosby, and U266 cell lines (Fig. 6.2D). In contrast, MM1.S 
was the only cell line tested in which HIF2 expression was O2-dependent. These findings 
are generally similar to other reports describing HIF1 expression in MM cells (3, 10, 14). 
Culturing 8226 and OPM2 with low oxygen (0.1% 24hrs) didn’t affect the expression of 
the pro-survival factor Bcl-2, but did inhibit Bcl-xl and MCL-1 in OPM2 and 8226, whilst 
survivin was only downregulated in OPM2 cells (Fig. 6.2E).  Survivin has previously been 
reported to play a role in HIF-regulated survival of myeloma cells and thus may be an 
important target for future studies (12). Low pO2 also upregulated the pro-apoptotic factors, 
BNiP3 (a known HIF target), BID, and BAX.  We wish to point out that it isn’t clear if the 
changes described above are specifically due to HIF activation (and as such could be a 
target for HIF-PA) or represent general physiological stresses in cell caused by low pO2.  
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HIF-PA inhibits the hypoxic response in MM cells 
 HIF1 siRNA was used to knockdown the baseline HIF1 expression in 8226 cells (Fig. 
6.3A), and importantly, this also inhibited the hypoxia-mediated upregulation of HIF1 
(Fig. 6.3A compare lanes 1 and 3 and 4 and 6) but not the expression of HIF2 protein. 
Silencing HIF1 with siRNA significantly inhibits HRE-LUC reporter activity in 8226 
HRE-luciferase (HRE-LUC) transfected reporter cells (Fig. 6.3B). It should be noted that 
in these experiments, HIF1 siRNA only inhibited about 50% of the HRE-LUC activity, 
which we believe is due to HIF2-mediated LUC activity, thus explaining the partial 
response we see. We also found that HIF-PA could inhibit the hypoxic response in 8226 
reporter cells. As shown in Fig. 6.3C, hypoxic conditions (0.1% O2, 24hr) induced (by ~2-
3 fold) LUC activity compared to baseline and HIF-PA inhibited about 40-50% (4 
Fig. 6.4.  HIP-PA sensitizes MM cells to hypoxia. (A) 8226 treated 
for 72 hr. (B) OPM2 treated for 24 hours. Apoptosis was 
measured by cleaved caspse 3.  Cells were cultured under 
normoxic (22%O2) or hypoxic conditions (0.1% O2) with 
indicated concentration of HIF-PA or control PA.  Data are 
means  SEM of 3 independent experiments. Brackets comparing 
control with treatment *=p<0.05.  
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independent experiments, p<0.05) of this hypoxia-induced effect. As a negative control, 
non-HRE-sequence targeting CO-PA recognizing the unrelated sequence, 5’-WGGWCW-
3’, didn’t significantly inhibit LUC activity. Similar results were seen in HRE-LUC 
expressing U266 and OPM2 cell lines (data not shown). In a previous study, it was shown 
that treatment with HIF-PA affected expression of a subset of hypoxia-induced genes 
containing HREs of the sequence 5′-(T/A)ACGTG-3′ that was similar to the level of 
inhibition observed when HIF was silenced by siRNA and by the DNA binding drug, 
 
Fig 6.5. HIF-PA inhibits 8226 tumor growth in SQ xenograft 
model. (A) Change in 8226 tumor volume in HIF-PA treated 
NOD/SCID mice.  Arrows indicate days of injection. * p<0.05 
(B) Uptake of FITC-labeled HIF-PA  (3 injections, every other 
day) assayed using fluorescent imaging of live animals.  Arrows 
indicate location of SQ 8226 tumors. (C) Confocal fluorescent 
microscopy of excised tumors, demonstrating nuclear uptake of 
HIF-PA. 
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Echinomycin (20). However, in this study, the effect of HIF-PA-mediated inhibition of 
gene expression was not studied for cells cultured under hypoxic conditions. To address 
this, we tested if VEGF gene transcription (a known target of HIF) was inhibited by HIF-
PA in MM cells. As shown in Fig. 6.3D, culturing 8226 cells under hypoxic conditions 
(0.1% O2, 24hrs) induced VEGF mRNA (by ~3-4 folds) and HIF-PA significantly (3 
independent experiments p<0.05) inhibited this effect. Additionally, VEGF protein 
(measured by ELISA) in the supernatant of cells cultured in low pO2 was also significantly 
downregulated (p<0.05)(Fig. 6.3E). Altogether, these data support the hypothesis that HIF-
PA can inhibit the HIF-mediated adaptive hypoxic response in MM.  
 
HIF-PA sensitizes MM to hypoxia 
We expect that inhibiting the adaptive hypoxic response will sensitize MM cells to 
hypoxia-mediated apoptosis based on our preliminary data. To test this, we cultured MM 
cells under normoxic or hypoxic conditions (0.1% O2, 72 hours) in the presence of HIF-
PA or control.  As shown in Fig. 6.4, HIF-PA had little effect on normoxic 8226 cells (Fig. 
6.4 white bars), but HIF-PA treatment of hypoxic 8226 cells induced a significant and dose-
dependent hypoxia-mediated killing (an increase in ~20% to ~60%)(ANOVA, P<0.05) 
(Fig. 6.4A left panel). OPM2 cell lines were even more sensitive to hypoxia and HIF-PA, 
(ANOVA, P<0.05) with similar increases in apoptosis being observed by only 24 hrs (Fig. 
6.4B right panel). The control, CO-PA, had no effect on hypoxia-mediated apoptosis in 
either cell line. Similar results on hypoxia-mediated sensitization were seen with MM1S 
and U266 cells (data not shown). These data represent the results of 3 independent 
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experiments and support our hypothesis that inhibiting the adaptive hypoxic response 
with HIF-PA can overcome MM resistance to hypoxia-mediated apoptosis.    
 
As an in vivo correlate of the above data, the anti-MM effects of HIF-PA were also tested 
in a NOD/SCID xenograft model of subcutaneous (SQ) 8226 tumors (47-49). The mice 
were treated with 5 IP injections of HIF-PA (100nmol) or vehicle control every other day 
and the change in tumor volume was measured with calipers. HIF-PA treatment was well 
tolerated by the mice, with only a small transient decrease in weight. HIF-PA induced a 
significant inhibition of tumor growth in treated mice compared to control mice (p<0.05) 
(Fig. 6.5A). In order to confirm uptake of HIF-PA, an additional group of mice (N=2 
mice/group) were given FITC-conjugated HIF-PA to measure compound uptake by 
fluorescent imaging (Fig. 6.5B). There was some auto-fluorescence signal in the bladder 
 
Fig. 6.6.  Photomicrographs of serial tumor sections from control 
or HIF-PA treated mice stained for hypoxia (brown stain) and 
apoptosis (cleaved caspase 3). *=corresponding geographic 
regions.  Arrow=areas of hypoxia and associated apoptosis. 
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and gut (Fig. 6.5B, mice #1 and #2) of control mice. However, in FITC-HIF-PA treated 
mice, a positive signal in the tumor nodules was noted (Fig. 6.5B see arrow in mouse #3 
and #4) and was confirmed by fluorescent confocal microscopy of excised tumors (Fig. 
6.5C). IHC for hypoxia and apoptosis of serial tumor sections is shown in Fig. 6.6 as 
described previously (49). Both control (top left panel) and HIF-PA (bottom left panel) 
treated tumors had regions of hypoxia (the brown stained areas), but the extent of hypoxia 
(as well as areas of necrosis) was greater in the HIF-PA treated tumors. Quantification of 
hypoxic regions (determined by area of positive staining) (10 tumors/group, 10 
fields/tumor) was ~35% in nodules harvested from the HIF-PA treated mice, compared to 
about 18% in the tumors from mice treated with vehicle control (p<0.05) (Fig. 6.7A). 
Necrotic regions within the HIF-PA treated tumors were greater than in control tumors, 
Fig 6.7.  (A) Area of hypoxic regions in tissue sections stained 
for pimonidazole.  (B).  Apoptotic index, a measure of 
#apoptotic nuclei/unit area with regions of hypoxia or 
“normoxia”.  (C) ELISA analysis of VEGF concentration in 
tumor lysate.  *=P<0.05.  Values are means +/- 95% CI. 
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and there was a strong physical correlation between areas of hypoxia and apoptosis 
(Fig. 6.6, bottom right panel), whilst apoptotic cells were evenly distributed in the control 
tumors (Fig. 6.6, top right panel). The apoptotic index (number of apoptotic cells/unit area) 
was used to quantify cell death by examining serial sections for hypoxic (determined by 
brown staining), and “normoxic” (determined by a lack of staining) regions and counting 
the number of apoptotic cells in the corresponding areas (10 tumors/group, 10 
fields/region). As shown in Fig. 6.7B, there was an approximate 3-4 fold increase in 
apoptotic cells in the hypoxic regions of tumors from the HIF-PA treated mice compared 
to hypoxic regions of the control tumors (p<0.05). HIF-PA also significantly inhibited 
VEGF expression in tumor lysate by ~50% when compared to control tumors (Fig. 6.7C). 
Our data supports the hypothesis that HIF-PA can target VEGF and angiogenesis in vivo 
but we don’t think that inhibition of VEGF-mediated inhibition of angiogenesis is the only 
explanation for these results. For example, HIF-PA sensitized MM cells to hypoxia-
mediated apoptosis in vitro, a situation in which VEGF and angiogenesis is likely not 
important to MM survival.  
 
Anti-tumor effects of HIF-PA against MM engrafted in the BM. 
We’ve developed an orthotopic, “disseminated” BM-engrafted model (based on that of 
Miyakawa (50, 51)) using LUC2-transfected 8226 cells that will allow us to study MM 
engrafted in the BM. As shown in Fig. 6.8A, NOG mice challenged with 8226LUC cells 
developed engrafted tumors determined by using bioluminescence and X-ray analysis (Fig. 
6.8A). In these mice, 20-50% of the bone marrow cells from inoculated mice were positive 
for human CD45 as confirmed by flow cytometry using FITC-conjugated anti-huCD45 
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antibody (Fig. 6.8B) and by IHC of in situ CD45+ 8226 cells in the mouse femurs. 
Gross histological analysis of the mice didn’t show tumor formation in other tissues (i.e., 
liver, lung, spleen, or kidney). Other MM cell lines (e.g., OPM2, U266, and H929) are 
currently being developed and tested using this model. 
 
Next, we performed a pilot experiment in which NOG mice (N=8 mice/group) with BM 
engrafted 8226LUC cells were given HIF-PA or vehicle control as described above for our 
SQ model. Fig. 6.9A shows that there was no significant (ANOVA, p<0.10) inhibition of 
 
Fig 6.8. NOG mice challenged IV with 8226-LUC expressing 
cells.  (A) Imaging of 12 mice on day +20 post-challenge with 
8226LUC showing positive signal associated with long bones, 
skull, and spine. (B) BM harvested from mice challenged with 
8226LUC or PBS and stained for huCD45 antibody (C).  IHC of 
femurs of mice challenged with 8226LUC or PBS. Serial sections 
were stained with pimonidazole or huCD45.
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tumor growth in the BM and that increasing samples size will be required. Lack of 
significance was probably due to the small N and large variations in bioluminescence signal 
in the control mice. Representative images taken on day +2, +6 and +13 show both a 
decrease in LUC activity as well as a general shrinkage of individual tumor foci in the HIF-
PA treated mice (Fig. 6.9B). In fact, we noted that in control mice, the tumor foci tended 
to grow and merge during the course of the experiment, in contrast to HIF-PA treated mice, 
in which the foci remain relatively small and isolated.  This suggests to us that HIF-PA 
may inhibit both tumor growth and migration within the skeleton, suggesting further 
experiments to test this hypothesis. 
 
Fig 6.9. HIF-PA inhibits 8226 tumor growth in BM.  (A). NOG 
(8/group) were challenged IV with 8226-LUC cells.  Animals were 
given 5 IP injections of HIFA (100nmol) or vehicle control (arrows 
indicate days of injection).  Luciferin bioluminescence was 
measured and data is presented as average radiance  95% CI.  
*p<0.10.  (B) Representative pictures of mice imaged on day 2, day 
6, and day 13 in control and HIF-PA treated mice showing change 
in Luciferin activity. 
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Fig 6.10. (A) Differential sensitivity of AKT/mTOR pathway in 
MM cells to 24hr hypoxia (0.1%) or CoCl2 (100M) treatment.  
Bracket indicates OPM2 treated with either hypoxia or CoCl2. (B) 
OPM2 cells were cultured under normoxic or hypoxic (0.1%) 
conditions for 24 hrs and then allowed to re-oxygenate under 
normoxic culturing conditions for indicated time periods. 
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Effects of AKT/mTOR pathway activation on regulation of HIF-PA sensitivity: We 
have previously demonstrated that sensitivity of MM cells to mTOR inhibitors was 
correlated to heightened AKT activity in vivo and this was correlated with the inhibition of 
VEGF and angiogenesis (45, 47-49).  Based on that we initially hypothesized that simply 
the induction of hypoxic stress could kill MM cells. However, as shown in Fig. 6.2, oxygen 
stress alone doesn’t explain our in vivo observations, as MM tend to be resistant to low 
pO2. In fact, MM cells that are most resistant to mTOR inhibition (and are characterized 
by quiescent  AKT) also tend to be the most resistant to hypoxia (ie., 8226 and U266), 
whilst cells with hyperactive AKT tended to be the most sensitive (i.e.,OPM2) (52).  
 
One potential mechanism is that hypoxia induces REDD1 expression, a hypoxia-
sensitive inhibitor of mTOR (53).  Therefore, we asked what were the effects of hypoxia 
on the mTOR pathway in our model.  As shown in Fig. 6.10, hypoxia (or treatment with 
the hypoxia mimic CoCl2) induces REDD1 expression and inhibits the phosphorylation of 
p70S6 kinase, a downstream target of mTOR (54) (Fig. 6.10A).  Hypoxia mediated 
inhibition of p70 was transient, returning to normal within 2 hr following reoxygenation of 
the cells (Fig. 6.10B). On the other hand, hypoxia has only slight effects on AKT 
phophorylation in 8226 and OPM2 cells and actually increases AKT phosphorylation at 
T308 in U266 cells. There is also evidence that IGF-1 and IL-6-mediated signaling via 
AKT induces HIF activity and potentiates survival in MM cells (12).  Finally, mutions in 
PTEN (tumor supresson gene that regulates AKT) leads to increase HIF activity (55). 
Therefore, based on this and our previous work, we will test if sensitivity to HIF-PA is 
regulated by the activation of AKT/mTOR pathway in MM cells. To achieve this, we’ll 
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use isogenic U266 cells that express a constitutively active AKT allele (45) as well as 
in ANBL-6 cells.  The effects of HIF will be validated using our knockdown cells as 
described above.  Specifically, we’ll test if sensitivity to HIF-PA is correlated to 
AKT/mTOR activity.   
In recent studies, it was shown that the hypoxia confers resistance to melphalan- or 
bortezomib-mediated apoptosis in MM cells, and silencing HIF1 expression restored 
sensitivity (12, 41). However, targeting HIF using siRNA may not be clinically feasible 
approach, and may be limited due to its failure to target HIF2. Therefore, we would argue 
that abrogating HIF’s ability to bind to the HRE using HIF-PA is a more effective way to 
overcome chemoresistance in MM. To test this hypothesis, MM cell lines and patient 
samples will be cultured in vitro under normoxic or hypoxic conditions and treated with 
HIF-PA in combination with bortezomib, melphalan, or mTOR inhibitors.  These drugs 
were selected because they are either currently utilized anti-MM therapies (bortezomib and 
melphalan) or have been implicated in hypoxia-mediated apoptosis (mTOR inhibitors) in 
MM.  In initial experiments, we’ll measure the viability (by MTT assay), cell cycle transit 
(by hypotonic PI), and induction of apoptosis (using a cleaved caspase-3 assay kit) at 
various time points. We’ll also collect RNA and protein to study the effects combination 
therapy on gene expression. The evaluation of drug-drug and drug-hypoxia interactions 
will be determined by isobologram and combination index (CI) analysis as previously 
described in our recently published study (56).  
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Our past studies have established that 8226 cells are resistant to mTOR inhibitors due, at 
least in part, to AKT dependent regulation of the internal ribosome entry site (IRES)-
mediated cap-independent salvage pathway that allows for translation of critical RNA 
species in the face of mTOR inhibition by rapalogs (i.e., rapamycin (RAPA) and 
temsirolimus) (45, 48, 49, 57, 58).  We also demonstrated a correlation between RAPA-
mediated inhibition of VEGF expression and angiogenesis with the induction of apoptosis 
in MM tumors in vivo (47, 48).  Since hypoxia inhibits the mTOR pathway (53, 59, 60) 
and cap-dependent translation (61), this suggests a role of IRES activity in regulating MM 
Fig 6.11. Combination of HIF-PA and Rapa treatment overcome 
resistance to hypoxia-mediated apoptosis.  Cells were cultured 
under normoxic or hypoxic (0.1%) conditions with indicated 
drugs for 72hr.  Values are mean  SEM of 3 independent 
experiments.  Brackets and * indicates * p<0.05). 
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sensitivity to hypoxia (62).  However, as shown in Fig. 6.2A, hypoxia alone isn’t 
sufficient to kill 8226 MM cells.  Therefore, we tested whether or not inhibiting mTOR-
mediated translation could overcome resistance to hypoxia, the rationale being that 
inhibition of protein translation induced by the hypoxic response could sensitize the cells 
to apoptosis. Surprisingly, we found that mTOR inhibition had only a modest effect on 
apoptosis in MM cells cultured under hypoxic (0.1% O2) conditions (Fig. 6.11, see white 
bars). However, the RAPA-resistant cell line, 8226, demonstrated a significant and 
synergistic HIF-PA-mediated sensitization to apoptosis in combination with RAPA, 
suggesting that targeting both the transcription and translation of hypoxia-induced genes 
would be an effective anti-MM strategy (Fig. 6.11, see grey and black bars and bracketed 
area). To expand on these findings, we’ll study combination treatment of HIF-PA and 
mTOR inhibitors, including members of the rapalog family (e.g. rapamcyin, temsirolimus) 
that inhibit the mTOR complex 1 (mTORC1) and the new family of mTOR complex 1 and 
complex 2 (mTORC1/2) inhibitors (e.g., PP242) (63).  Finally, we’ll also study 
combination therapy of HIF-PA with bortezomib (a proteosome inhibitor) and melphalan 
(a nitrogen mustard alkylating agent) that were selected because they represent standard 
therapies for MM.  As stated above, very interesting data has been presented indicating that 
hypoxia can confer resistance to these drugs in MM. Since these therapeutics are standard 
for treating MM, we believe that determining if HIF-PA can overcoming MM resistance is 
clinically relevant and will be a major goal of this AIM. 
 
 
  
182
Data and Statistical Analysis: All data collected will be compiled and maintained 
using the computer program Excel. Initial data exploration and analysis of all variables will 
be performed using summary tables (mean, standard deviation, and ranges) box plots, and 
line graphs. The null hypothesis (that there is no difference from the control) will be tested 
using one-way analysis of variance (ANOVA), Student t-tests, multiple linear regression 
models, and post hoc Tukey-Kramer pair-wise comparisons. A P-value < 0.05 will be 
considered statistically significant for rejecting the null hypothesis.  The PI has access the 
UCLA Semel Institute Statistics Core that will provide expert guidance and consultation 
in the design and analysis of experiments with the appropriate level of statistical power. 
 
Power analysis for mouse studies: A power analysis predicts 95% power to detect 
differences of 30% or greater in changes in our primary variable (tumor volume) using a 
sample size of 8 mice/group. The effect size for changes in tumor volume in drug-treated 
mice compared to controls was estimated from our preliminary data and previous studies 
to be between 30-50%. However, only approximately 75-100% of mice challenged with 
tumor cells (depending upon cell line) develop a SQ or BM engrafted tumors. Thus, to 
ensure 8 mice/group, a total of 10-16 mice will be injected with tumor cells per experiment.  
Overall, we expect to utilize about 200 mice/year. 
 
Power analysis for patient samples: We assumed that the ED50 for HIF-PA-mediated 
cytotoxicity will be a continual variable under hypoxic conditions and dichotomized 
samples into high (i.e. constitutive expression) or low (no expression) for HIF1 protein 
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examples. We also assumed that 33% of patient samples express “high” HIF1 based 
on previous literature (9). Thus, we estimate we’ll need 25 patients to have 80% power and 
detect at least a 2x fold difference in the ED50 at a significance level of =0.05 (calculated 
by a 2 sided t-test). In consultation with Dr. Lichtenstein, we anticipate recruiting ~7-10 
patient samples/year, which should allow us to complete these studies in the time frame of 
this MERIT. We are cognizant of the fact that patient history (such as newly diagnosed 
versus relapsed disease) will contribute to the variability of our model, but would argue 
that addressing these variables are outside the initial scope of this application. However, if 
our pre-clinical results are promising, we will expand our experimental design to 
incorporate these additional factors. 
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